Eurolife Mini Symposium: Therapeutic Vaccines for Cancer



W. Wolfgang Fleischhacker, President, Medical University of Innsbruck

Immuno-Oncology in Innsbruck

Zlatko Trajanoski, Bioinformatics, Medical University of Innsbruck

Oncolytic virotherapy for in situ cancer vaccination

Guido Wollmann, Virology, Medical University of Innsbruck

Eurolife Distinguished Lecture

Therapeutic cancer vaccination in combination with modulators of the microenvironment to boost tumor specific T cell immunity

Sjoerd van der Burg, Leiden University Medical Center, The Netherlands

19 November 2018, 17:15 MZA - Lecture Hall Anichstraße 35, 6020 Innsbruck





Sjoerd H. van der Burg, Ph.D. is a professor in the immunotherapy of cancer, with a special emphasis on immunomonitoring at the department of medical oncology of the Leiden University Medical Center where he leads the experimental cancer immunology and therapy group consisting of about 30 scientists and technicians. The aim of his program is to implement immunotherapy as treatment modality for patients with solid tumors. The program is focused on the exploration of key factors in host-tumor interactions that determine successes and failures in immune control of cancer in order to drive the improvement of immunotherapeutic strategies against solid tumors. The fundamental, translational and clinical studies in his group has led to insights in the role of the tumor immune microenvironment, immune suppression and escape in cancer progression and therapy resistance. Furthermore, it led to the development of a powerful therapeutic vaccine concept and an adoptive cell transfer strategy for the treatment of cancer.